Growth Opportunities in Biologics Contract Development and Manufacturing Organizations, 2024 2029

Report Summary: 

The global biologics CDMO market was valued at USD 19.68 billion in 2023 and is projected to reach USD 43.85 billion by 2029, growing at a CAGR of 14.3% (2023–2029). Market expansion is fueled by the rise of cell & gene therapies, synthetic nucleic acids, bispecific antibodies, and viral vector-based treatments, alongside growing outsourcing demand from biopharma.

Key Market Trends & Insights

• Emerging modalities (CGT, ADCs, nucleic acids) driving faster clinical timelines and new CDMO service needs.
• Strategic M&A & capacity expansion strengthening global CDMO capabilities.
• Shift toward flexible, end-to-end service models replacing fee-for-service structures.
• US IRA & BIOSECURE Act influencing outsourcing demand and global supply chains.
• Top 5 players (Lonza, Samsung Biologics, Catalent, Boehringer, Thermo Fisher) control 64.5% of revenue, but niche/specialized CDMOs are gaining ground.

Market Outlook

• 2023 Market Size: USD 19.68 Billion
• 2029 Market Size (Est.): USD 43.85 Billion
• CAGR (2024–2031): 14.3%

Scope & Coverage

• Segmentation by Product: Drug substance, drug product
• By Cell Expression Type: Microbial, mammalian, others (insect, plant, cell-free)
• By Modality: CGTs, antibodies, proteins/peptides, vaccines
• Regions Covered: North America, Europe, Asia-Pacific, Latin America & Middle East

Market Overview:

The biologics CDMO market is undergoing a transformative shift, driven by the evolution of complex therapeutic modalities and increasing outsourcing needs. As of 2023, biologics made up 44% of the global therapeutic pipeline, with monoclonal antibodies and recombinant proteins continuing to dominate. However, the pace of innovation in these established biologics segments has slowed, giving way to rapid growth in emerging modalities such as cell and gene therapies (CGT), synthetic nucleic acids, bispecific antibodies, antibody-drug conjugates (ADCs), and viral vector-based treatments.

These shifts are reshaping the biologics contract development and manufacturing organization (CDMO) market, as biopharmaceutical companies pivot toward faster clinical development timelines and cost-efficient production models with lower cost of goods sold (COGS). To keep pace with this trend, biologics CDMOs are recalibrating their strategies by enhancing capabilities across advanced manufacturing technologies, strengthening supply chains, and establishing robust partnerships that enable flexible, scalable, and compliant production.

While macroeconomic and policy developments—particularly the US Inflation Reduction Act (IRA) and the BIOSECURE Act—pose challenges to global drug innovation and CDMO service demand, the market shows signs of stabilization. Venture capital firms have adjusted funding strategies to preserve capital, and biotech companies are cautiously resuming early-phase drug development. Consequently, despite a temporary slowdown, the biologics contract development market is expected to experience renewed momentum from 2024 onward.

The biologics CDMO market report from Frost & Sullivan forecasts a notable resurgence, especially from emerging biopharma and early-stage developers. The market’s medium-term trajectory will be shaped by strategic M&A activities, capacity expansions, and an increased focus on service differentiation. Key areas of expansion include modality-specific support, such as viral vector manufacturing, cell therapy processing, and nucleic acid formulation services.

The report provides segmented revenue forecasts across modalities, expression systems, product types, and key geographic regions from 2024 to 2029. It also offers actionable insights into the business models and strategic imperatives driving success in the biologics contract development and manufacturing organization CDMO market. With demand rebounding and innovation accelerating in next-generation biologics, Bio-CDMOs that invest in flexible infrastructure, end-to-end solutions, and regulatory readiness are well-positioned to capitalize on future growth opportunities.

Revenue Forecast – Biologics CDMO Market

The biologics CDMO market is on a strong upward trajectory, reflecting the surging demand for complex biologic therapies and the continued shift toward outsourcing among biopharmaceutical companies. Valued at USD 19.68 billion in 2023, the market is projected to reach an impressive USD 43.85 billion by 2029, expanding at a compound annual growth rate (CAGR) of 14.3% from 2023 to 2029.

Revenue Forecast

The revenue estimate for the base year 2023 is $19.68 billion, with a CAGR of 14.3% for the study period 2023-2029.

Scope of Analysis – Biologics CDMO Market

This study offers an in-depth examination of the biologics CDMO market, presenting a detailed 56-year revenue forecast and covering critical trends shaping the outsourcing landscape. 

Geographically, the report provides segmentation and revenue insights across North America (NA), Europe, Asia-Pacific (APAC), and Latin America & the Middle East (LATAM & ME). These regions represent the key drivers of global demand in the biologics CDMO market, each offering unique opportunities based on their regulatory environment, innovation maturity, and biologics production capabilities.

The biologics CDMO market report also highlights how emerging business models—such as reserved capacity agreements and flexible manufacturing solutions—are transforming the traditional fee-for-service approach. These models are gaining traction as biopharma companies seek long-term, scalable partnerships to address the growing complexity of biologics pipelines.

Segmentation for this analysis includes drug type, cell expression type, modality, and region. Special focus is placed on novel cell expression systems, including cell-free, insect-based, and plant-based platforms, which are categorized under "other cell expression types." This reflects the expanding technological scope of the biologics CDMO market as companies explore new therapeutic modalities and manufacturing techniques.

Overall, the report provides strategic insights for stakeholders to understand market drivers, identify high-growth segments, and align their offerings to capitalize on evolving trends in the global biologics CDMO ecosystem.

Segmentation– Biologics CDMO Market

The biologics CDMO market report segments the industry by product type, cell culture type, therapeutic modality, and region, offering a structured view of the biologics outsourcing landscape and highlighting emerging trends in the biologics contract development market.

Product Type

• Drug Substance: This category includes biologically active components such as live, inactivated, or dead cells and tissues derived from sugars, proteins, or nucleic acids. These form the core of drug manufacturing processes and are a critical focus for CDMOs.
• Drug Product: Refers to the finished dosage form derived from a biological source—either synthesized or extracted. The biologics CDMO market continues to expand its capabilities in this area to support commercial and clinical-grade production for global clients.

Cell Culture Type

• Microbial: These are fast-growing organisms cultivated in controlled media, used extensively in producing recombinant proteins and biosimilars.
• Mammalian: Representing the fastest-growing segment in the biologics CDMO market, these cells are cultured from mammalian tissues and used for producing complex biologics like monoclonal antibodies (mAbs).
• Others: This includes non-microbial and non-mammalian systems such as plant, insect, and cell-free expression systems. These platforms offer flexibility and are gaining momentum for specialized biologics manufacturing.

Modality

• Cell and Gene Therapies (CGT): A major growth driver in the biologics CDMO market, CGTs involve delivering therapeutic genes or cells to restore normal function. CDMOs are expanding capabilities to support CAR-T cell therapies, gene editing, and viral vector production.
• Antibody Therapeutics: Antibodies, particularly monoclonal antibodies, remain central to the Biologics CDMO market. CDMOs support both traditional hybridoma methods and modern recombinant approaches using mammalian or insect expression systems.
• Proteins and Peptides: Includes therapeutic proteins such as enzymes, hormones, and peptides from natural or recombinant origins. CDMOs play a key role in scaling these molecules from discovery to commercial production.
• Vaccines: Biotechnological advances, especially in mRNA and DNA vaccines, are transforming the biologics CDMO market. CDMOs are investing in end-to-end solutions to meet rising demand for both prophylactic and therapeutic vaccine development.

Regional Coverage

The biologics CDMO market report spans four major regions:

• North America (NA) – Leading in innovation and early-stage biologics outsourcing.
• Europe – A stronghold of regulatory expertise and high-quality CDMO operations.
• Asia-Pacific (APAC) – Rapidly growing outsourcing hub with competitive manufacturing costs.
• Latin America & Middle East (LATAM & ME) – Emerging interest driven by local pharmaceutical expansion and favorable investment climates.

Growth Drivers and Restraints Analysis– Biologics CDMO Market

Growth Drivers

• Rising development costs, reduced profit margins, and stricter price ceilings are driving pharmaceutical companies to outsource services instead of building in-house.
• Biopharma firms are mitigating risks through pipeline reprioritization, externalizing non-core activities, and outsourcing complex processes via strategic risk-sharing partnerships.
• Emerging biopharma firms, holding 70% of the R&D pipeline, face resource constraints and thus rely heavily on financial sponsorship and external contract service providers.
• Varying country regulations drive pharma firms to outsource to CDMOs for regulatory support, approvals, and advanced technologies that enable rapid, scalable drug delivery.

Growth Restraints

• Rising input costs and fewer COVID-19 projects are pressuring CDMO revenues, driving focus on CAPEX control, cost optimization, efficiency, and lean manufacturing.
• CDMOs face skilled labor shortages, making recruitment and retention difficult, which risks delays and quality issues in drug development and advanced therapies.
• Biopharma expands in-house capabilities through acquisitions of CROs/CDMOs to secure IP and reduce outsourcing, intensifying competition and pressuring margins.
• CGT and ADC manufacturing requires heavy investment, strict compliance, and adaptable facilities due to complexity, high costs, low patient volumes, and scalability challenges.

Competitive Landscape - Biologics CDMO Market

The biologics CDMO market is characterized by intense competition, with more than 200 active players globally offering a range of services across drug development and manufacturing. According to the latest biologics CDMO market report, the top 5 competitors—Lonza, Boehringer Ingelheim BioXcellence, Samsung Biologics, Catalent, Wuxi Biologics  and Thermo Fisher Scientific—collectively accounted for more than 6% of total market revenue in 2023, highlighting a concentrated but expanding ecosystem.

Key competitive factors in the biologics CDMO market include pricing strategy, technological innovation, manufacturing reliability, regulatory compliance, depth of scientific expertise, global supply chain efficiency, and regional as well as international footprint. Moreover, strong customer relationships and a proven ability to scale production remain essential differentiators.

Leading service providers in the biologics CDMO market cater to a diverse set of end-user verticals, including biopharmaceutical companies, academic research institutions, and clinical-stage biotechnology firms. The growing complexity of biologics developments such as in cell and gene therapies—demands CDMOs with end-to-end capabilities and global regulatory alignment.

Noteworthy competitors in the market include AGC Biologics, FUJIFILM Diosynth Biotechnologies, and Pfizer CenterOne. These companies continue to strengthen their foothold through strategic mergers, acquisitions, and technology partnerships. For example, Biovian’s merger with 3P Biopharmaceuticals and Novo Holdings’ acquisition of Catalent underscore the consolidation trend in the biologics CDMO market. Similarly, Ajinomoto’s acquisition of Forge Biologics signifies growing interest in advanced therapy platforms.

Other notable players like AbbVie Contract Manufacturing, IDT Biologika, Rentschler Biopharma, Avid Bioservices, Piramal Pharma Solutions, and KBI Biopharma are also emerging as critical participants in the market’s ongoing transformation.

This competitive landscape suggests that while the biologics CDMO market is currently led by a few dominant players, opportunities abound for mid-sized and specialized CDMOs that offer niche capabilities, advanced technologies, or geographic advantage.